Clinical trials: High Grade Gliomas
Glioma, Glioblastoma
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2).
- Conditions
- Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma
- Trial name
- NCT03718767
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Malignant Glioma, High Grade Glioma
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of…
- Trial name
- ACTION (NCT03334305)
- Testing
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Glioblastoma, Surgery
Neoadjuvant Chemoradiation for Resectable Glioblastoma
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the…
- Conditions
- Glioblastoma, Surgery, High Grade Glioma
- Trial name
- NeoGlio (NCT04209790)
- Testing
- Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Geisinger Clinic
High Grade Glioma, Ependymoma
HUMC 1612: Optune NovoTTF-200A System
The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
- Trial name
- NCT03128047
- Testing
- Optune NovoTTF-200A System
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Hackensack Meridian Health
High Grade Glioma, Astrocytoma, Grade III
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
This is a Phase 2 study of newly diagnosed patients with high grade glioma (HGG) undergoing standard radiation therapy and temozolomide treatment.
- Conditions
- High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
- Trial name
- BMX-HGG (NCT02655601)
- Testing
- BMX-001, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 177 people
- Sponsor
- BioMimetix JV, LLC
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Glioma, Glioblastoma Multiforme
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- BrTK02 (NCT00589875)
- Testing
- CAN-2409, Valacyclovir, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Candel Therapeutics, Inc.
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma.
- Trial name
- NCT03463265
- Testing
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aadi Bioscience, Inc.
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma Multiforme, Anaplastic Astrocytoma
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
- Trial name
- NCT02885324
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Glioma, High Grade Glioma
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)…
- Conditions
- Glioma, High Grade Glioma, Pontine Tumors
- Trial name
- NCT03352427
- Testing
- Dasatinib, Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
In this research study the investigators want to learn more about the effects, both good and bad, when the study drug Ribociclib is given after radiation therapy.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
- Trial name
- NCT02607124
- Testing
- Ribociclib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
High Grade Glioma
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
This randomized, open-label, multicenter, 2-arm study will investigate the efficacy, safety, tolerability and pharmacokinetics of bevacizumab when added to postoperative radiotherapy with concomitant and adjuvant TMZ as compared…
- Trial name
- NCT01390948
- Testing
- Bevacizumab, Radiotherapy, Temozolomide (TMZ)
- Where
- 53 sites in Australia, Austria and 12 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
HIGH GRADE GLIOMA
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The Primary Objectives are: To determine the extent by which TH-302 is able to penetrate the blood brain barrier and affect tumor tissue To assess the safety of single dose TH-302 in patients with high grade glioma undergoing…
- Trial name
- NCT01403610
- Testing
- TH-302 preoperative, TH-302 (escalating) with bevacizumab 10mg/kg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio